NeuroNEXT: accelerating drug development in neurology

NeuroNEXT: accelerating drug development in neurology

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Lancet neurology 2012-02, Vol.11 (2), p.119-119
1. Verfasser: The Lancet Neurology
Format: Artikel
Sprache:eng
Schlagworte:
Biomarkers
Clinical Trials, Phase II as Topic
Humans
Multicenter Studies as Topic
National Institute of Neurological Disorders and Stroke (U.S.)
Nervous System Diseases - diagnosis
Nervous System Diseases - drug therapy
Neurology
United States
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 119
container_issue 2
container_start_page 119
container_title Lancet neurology
container_volume 11
creator The Lancet Neurology
description
doi_str_mv 10.1016/S1474-4422(12)70008-X
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_917572678</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S147444221270008X</els_id><sourcerecordid>2574251051</sourcerecordid><originalsourceid>FETCH-LOGICAL-c493t-7ddf08576fc66970573ea31a0baa5a3bf8ad9f25b760d580e720c7c32cef06613</originalsourceid><addsrcrecordid>eNqFkE1P3DAQhi0EAgr8BNCKS9tDYDyO7YQDVYVoQUL0UJD2ZnmdCTJkk8VOVtp_X-9H98CFi8eynnk88zJ2yuGCA1eXf3mu8yzPEb9x_K4BoMjGO-xw86zk7vaOeMC-xPgKgDwv-D47QEQlEfQhk480hO7xdvx0NbLOUUPB9r59GVVhSAfNqelmU2r7kW9H7ZJtupfFMdurbRPpZFOP2POv26ebu-zhz-_7m58PmctL0We6qmoopFa1U6rUILUgK7iFibXSikld2KqsUU60gkoWQBrBaSfQUQ1KcXHEvq69s9C9DxR7M_UxDdnYlrohmpJrqVHpIpHnH8jXbghtGi5BRWKEKBMk15ALXYyBajMLfmrDwnAwy1TNKlWzjMxwNKtUzTj1nW3kw2RK1bbrf4wJ-LEGKIUx9xRMdJ5aR5UP5HpTdf7TL64_GFzjW-9s80YLittluIloYC1ZOjiuDGPxD_tHmmM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>918726339</pqid></control><display><type>article</type><title>NeuroNEXT: accelerating drug development in neurology</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><source>ProQuest Central UK/Ireland</source><creator>The Lancet Neurology</creator><creatorcontrib>The Lancet Neurology</creatorcontrib><identifier>ISSN: 1474-4422</identifier><identifier>EISSN: 1474-4465</identifier><identifier>DOI: 10.1016/S1474-4422(12)70008-X</identifier><identifier>PMID: 22265207</identifier><identifier>CODEN: LANCAO</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Biomarkers ; Clinical Trials, Phase II as Topic ; Humans ; Multicenter Studies as Topic ; National Institute of Neurological Disorders and Stroke (U.S.) ; Nervous System Diseases - diagnosis ; Nervous System Diseases - drug therapy ; Neurology ; United States</subject><ispartof>Lancet neurology, 2012-02, Vol.11 (2), p.119-119</ispartof><rights>Elsevier Ltd</rights><rights>2012 Elsevier Ltd</rights><rights>Copyright Elsevier Limited Feb 2012</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c493t-7ddf08576fc66970573ea31a0baa5a3bf8ad9f25b760d580e720c7c32cef06613</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/918726339?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995,64385,64387,64389,72469</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22265207$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>The Lancet Neurology</creatorcontrib><title>NeuroNEXT: accelerating drug development in neurology</title><title>Lancet neurology</title><addtitle>Lancet Neurol</addtitle><subject>Biomarkers</subject><subject>Clinical Trials, Phase II as Topic</subject><subject>Humans</subject><subject>Multicenter Studies as Topic</subject><subject>National Institute of Neurological Disorders and Stroke (U.S.)</subject><subject>Nervous System Diseases - diagnosis</subject><subject>Nervous System Diseases - drug therapy</subject><subject>Neurology</subject><subject>United States</subject><issn>1474-4422</issn><issn>1474-4465</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNqFkE1P3DAQhi0EAgr8BNCKS9tDYDyO7YQDVYVoQUL0UJD2ZnmdCTJkk8VOVtp_X-9H98CFi8eynnk88zJ2yuGCA1eXf3mu8yzPEb9x_K4BoMjGO-xw86zk7vaOeMC-xPgKgDwv-D47QEQlEfQhk480hO7xdvx0NbLOUUPB9r59GVVhSAfNqelmU2r7kW9H7ZJtupfFMdurbRPpZFOP2POv26ebu-zhz-_7m58PmctL0We6qmoopFa1U6rUILUgK7iFibXSikld2KqsUU60gkoWQBrBaSfQUQ1KcXHEvq69s9C9DxR7M_UxDdnYlrohmpJrqVHpIpHnH8jXbghtGi5BRWKEKBMk15ALXYyBajMLfmrDwnAwy1TNKlWzjMxwNKtUzTj1nW3kw2RK1bbrf4wJ-LEGKIUx9xRMdJ5aR5UP5HpTdf7TL64_GFzjW-9s80YLittluIloYC1ZOjiuDGPxD_tHmmM</recordid><startdate>20120201</startdate><enddate>20120201</enddate><creator>The Lancet Neurology</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>3V.</scope><scope>7RV</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>8AO</scope><scope>8C2</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20120201</creationdate><title>NeuroNEXT: accelerating drug development in neurology</title><author>The Lancet Neurology</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c493t-7ddf08576fc66970573ea31a0baa5a3bf8ad9f25b760d580e720c7c32cef06613</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Biomarkers</topic><topic>Clinical Trials, Phase II as Topic</topic><topic>Humans</topic><topic>Multicenter Studies as Topic</topic><topic>National Institute of Neurological Disorders and Stroke (U.S.)</topic><topic>Nervous System Diseases - diagnosis</topic><topic>Nervous System Diseases - drug therapy</topic><topic>Neurology</topic><topic>United States</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>The Lancet Neurology</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing &amp; Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>ProQuest Pharma Collection</collection><collection>Lancet Titles</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Psychology Database</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Lancet neurology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>The Lancet Neurology</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>NeuroNEXT: accelerating drug development in neurology</atitle><jtitle>Lancet neurology</jtitle><addtitle>Lancet Neurol</addtitle><date>2012-02-01</date><risdate>2012</risdate><volume>11</volume><issue>2</issue><spage>119</spage><epage>119</epage><pages>119-119</pages><issn>1474-4422</issn><eissn>1474-4465</eissn><coden>LANCAO</coden><cop>England</cop><pub>Elsevier Ltd</pub><pmid>22265207</pmid><doi>10.1016/S1474-4422(12)70008-X</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1474-4422
ispartof Lancet neurology, 2012-02, Vol.11 (2), p.119-119
issn 1474-4422
1474-4465
language eng
recordid cdi_proquest_miscellaneous_917572678
source MEDLINE; Access via ScienceDirect (Elsevier); ProQuest Central UK/Ireland
subjects Biomarkers
Clinical Trials, Phase II as Topic
Humans
Multicenter Studies as Topic
National Institute of Neurological Disorders and Stroke (U.S.)
Nervous System Diseases - diagnosis
Nervous System Diseases - drug therapy
Neurology
United States
title NeuroNEXT: accelerating drug development in neurology
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-22T21%3A18%3A51IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=NeuroNEXT:%20accelerating%20drug%20development%20in%20neurology&rft.jtitle=Lancet%20neurology&rft.au=The%20Lancet%20Neurology&rft.date=2012-02-01&rft.volume=11&rft.issue=2&rft.spage=119&rft.epage=119&rft.pages=119-119&rft.issn=1474-4422&rft.eissn=1474-4465&rft.coden=LANCAO&rft_id=info:doi/10.1016/S1474-4422(12)70008-X&rft_dat=%3Cproquest_cross%3E2574251051%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=918726339&rft_id=info:pmid/22265207&rft_els_id=1_s2_0_S147444221270008X&rfr_iscdi=true